ABSTRACT
Background New York City (NYC) was the epicenter of the COVID-19 pandemic in the United States. On April 17, 2020, the State of New York implemented an Executive Order that requires all people in New York to wear a face mask or covering in public settings where social distancing cannot be maintained. It is unclear how this Executive Order has affected the spread of COVID-19 in NYC.
Methods A dynamic compartmental model of COVID-19 transmission among NYC residents was developed to assess the effect of the Executive Order on face mask use on infections and deaths due to COVID-19 in NYC. Data on daily and cumulative COVID-19 infections and deaths were obtained from the NYC Department of Health and Mental Hygiene.
Results The Executive Order on face mask use is estimated to avert 99,517 (95% CIs: 72,723-126,312) COVID-19 infections and 7,978 (5,692-10,265) deaths in NYC. If the Executive Order was implemented one week earlier (on April 10), the averted infections and deaths would be 111,475 (81,593-141,356) and 9,017 (6,446-11,589), respectively. If the Executive Order was implemented two weeks earlier (on April 3 when the Centers for Disease Control and Prevention recommended face mask use), the averted infections and deaths would be 128,598 (94,373-162,824) and 10,515 (7,540-13,489), respectively.
Conclusions New York’s Executive Order on face mask use is projected to have significantly reduced the spread of COVID-19 in NYC. Implementing the Executive Order at an earlier date would avert even more COVID-19 infections and deaths.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Natural Science Foundation of China (81950410639 (LZ), 11801435 (MS), 11631012 (YX)); Outstanding Young Scholars Support Program (3111500001(LZ)); Xi'an Jiaotong University Basic Research and Profession Grant (xtr022019003(LZ), xzy032020032 (LZ)) and Xi'an Jiaotong University Young Scholar Support Grant (YX6J004(LZ)); the Bill & Melinda Gates Foundation (20200344(LZ)); China Postdoctoral Science Foundation (2018M631134, 2020T130095ZX); the Fundamental Research Funds for the Central Universities (xjh012019055, xzy032020026); Natural Science Basic Research Program of Shaanxi Province (2019JQ-187); Xi'an Special Science and Technology Projects on Prevention and Treatment of Novel Coronavirus Penumonia Emergency (20200005YX005); Zhejiang University special scientific research fund for COVID-19 prevention and control (2020XGZX056).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used only publicly available secondary data so ethics approval is not required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are attached in the Appendix
